What is LOPJLB’s current signal on YMAB?

LOPJLB’s latest quantitative signal on Y-mAbs Therapeutics, Inc. (YMAB) is BUY in a BULL regime. Signals are updated daily.

What market regime is YMAB in?

Y-mAbs Therapeutics, Inc. (YMAB) is currently classified in the BULL HMM market regime on LOPJLB.

Y-mAbs Therapeutics, Inc. (YMAB)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$8.61+0.00%Close

BUYBULL · day 25

RANGE

DATA 2025-09-16

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONE

Key stats

Market cap: $391M
Beta: 0.53

P/E (TTM): -12.85

1W: +0.35%
1M: +1.06%

vs SPY 1W: -0.81%
vs SPY 1M: -1.94%

Industry peers

FMP comparable companies · ranked by market cap

CLYMSELLClimb Bio, Inc.$630MCRISISQ 7$11.00+1.29%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Y-mAbs Therapeutics, Inc. is a biopharmaceutical firm already generating revenue, dedicated to discovering, advancing, and selling innovative antibody-derived therapies specifically designed to combat cancer within the United States. Its flagship product, DANYELZA, is a…

Employees: 104
Headquarters: US
Founded: 2018
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 45.4M
Float: 75.9%

ymabs.com ↗

Key executives

Michael Rossi — Chief Executive Officer, President & Director

Thomas — Founder, Chief Business Officer & Vice Chairman

Peter Pfreundschuh — Executive Vice President, Chief Financial Officer & Treasurer

SEC filings

EDGAR · CIK 17229640 · YMAB

Analyst consensus

Buy

Bullish850.0%

Neutral637.5%

Bearish212.5%

L $8.60Avg $12.71H $24.00

Target$12.71+47.62%

Last$8.61

FAQ

What is LOPJLB’s current signal on YMAB?: LOPJLB’s latest quantitative signal on Y-mAbs Therapeutics, Inc. (YMAB) is BUY in a BULL regime. Signals are updated daily.
What market regime is YMAB in?: Y-mAbs Therapeutics, Inc. (YMAB) is currently classified in the BULL HMM market regime on LOPJLB.
What does Y-mAbs Therapeutics, Inc. (YMAB) do?: Y-mAbs Therapeutics, Inc. is a biopharmaceutical firm already generating revenue, dedicated to discovering, advancing, and selling innovative antibody-derived therapies specifically designed to combat cancer within the United States. Its flagship product, DANYELZA, is a monoclonal antibody administered alongside granulocyte-macrophage colony-stimulating factor, targeting high-risk neuroblastoma…

Key stats

Industry peers

Prediction markets

Company news

FAQ